Ges, 3 mg+0.02 mg 28 pcs

Contraception

• Contraception
• Contraception and treatment of moderate acne (acne vulgaris)
• Contraception and treatment of severe premenstrual syndrome (PMS)

.

Indications

Contraception
Contraception and treatment of moderate acne (acne vulgaris)
Contraception and treatment of severe premenstrual syndrome (PMS)

Pharmacological effect

Pharmacotherapeutic group

Special instructions

If any of the conditions/risk factors listed below currently exist, the potential risks and expected benefits of combined oral contraceptives should be carefully weighed on an individual basis and discussed with the woman before she decides to start taking the drug. If any of these conditions or risk factors worsen, intensify, or appear for the first time, a woman should consult her doctor, who may decide whether to discontinue the drug.

Active ingredient

Drospirenone, Ethinylestradiol

Composition

Each active film-coated tablet contains:

Contraindications

Thrombosis and thromboembolism, as well as conditions preceding thrombosis, currently or in history, cerebrovascular disorders; migraine with focal neurological symptoms currently or in history; diabetes mellitus with vascular complications; multiple or severe risk factors for venous or arterial thrombosis, including complicated lesions of the heart valve apparatus; atrial fibrillation; diseases of the cerebral vessels or coronary arteries; uncontrolled arterial hypertension; major surgery with prolonged immobilization; smoking over the age of 35; pancreatitis with severe hypertriglyceridemia currently or in history; liver failure and severe liver disease (until liver tests return to normal); liver tumors (benign or malignant) currently or in history; severe renal failure, acute renal failure; adrenal insufficiency; identified hormone-dependent malignant diseases (including genital organs or mammary glands) or suspicion of them; vaginal bleeding of unknown origin; pregnancy or suspicion of it; breastfeeding period; hypersensitivity to any of the components of the drug Jess.

Side Effects

The following most common adverse reactions have been reported in women using the drug Jess in the “24+4” mode for the indications “Contraception” and “Contraception and treatment of moderate forms of acne (acne vulgaris)”: nausea, pain in the mammary glands, irregular uterine bleeding, bleeding from the genital tract of unspecified origin. These adverse reactions occurred in more than 3% of women. In patients using Jess for the indication “Contraception and treatment of severe premenstrual syndrome”, the following most common adverse reactions were reported (in more than 10% of women): nausea, pain in the mammary glands, irregular uterine bleeding.

Interaction

The effect of other drugs on the drug Jess

Overdose

No serious adverse events have been reported following overdose.

Storage conditions

The drug should be stored in a dry place, out of reach of children, at a temperature not exceeding 30°C.

Shelf life

5 years (blister with 28 tablets), 3 years (flex cartridge with 30 tablets).

Manufacturer

Bayer Weimar GmbH & Co. KG, Germany